WASHINGTON – The United States Food and Drug Administration (FDA) on Tuesday authorized Novavax’s updated COVID-19 vaccine, which is designed to include protection against the Omicron XBB.1.5 variant.
The FDA indicated in a statement that it authorizes the administration of this monovalent vaccine to people over 12 years of age.
Those who have been vaccinated against COVID-19 will only need one dose of the new Novavax vaccine, while those who have not yet received one will require two shots.
Dr. Peter Marks, director of the FDA’s Center for Biological Evaluation and Research, stated that the updated version of Novavax adds to the arsenal of drugs available against covid-19 and recommended that the population get vaccinated for the fall. .
The FDA also canceled the authorization to use the original Novavax vaccine as of Tuesday.
On September 11, it had approved the use of the updated Moderna and Pfizer/BioNTech vaccines, which use the messenger RNA technique, to combat variants such as the omicron XBB.1.5.
The updated vaccines from Moderna and Pfizer/BioNTech are approved for those 12 years and older and authorized for emergency use for people 6 months to 11 years old.
2023-10-03 23:37:26
#FDA #approves #updated #Novavax #vaccine #COVID19 #variants
